Literature DB >> 25284086

Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis.

Michelle L Davis1, Jasper A J Smits, Stefan G Hofmann.   

Abstract

INTRODUCTION: Social anxiety disorder (SAD) is a common mental health problem that tends to be chronic in nature; fortunately, effective pharmacotherapy options exist. The current study provides an updated meta-analytic review of their efficacy and potential guidelines for their application in SAD.
METHODS: A comprehensive search of the current literature yielded 39 randomized, pill placebo-controlled trials of pharmacotherapy for adults diagnosed with SAD. Data on potential moderators of treatment outcome were collected, as well as data necessary to calculate effect sizes using Hedges's g.
RESULTS: The overall effect size of pharmacotherapy for SAD is small to medium (Hedges's g = 0.39). The most effective pharmacotherapy type was phenelzine (Hedges's g = 1.14), followed by paroxetine (Hedges's g = 0.49), venlafaxine ER (Hedges's g = 0.45) and moclobemide (Hedges's g = 0.23).
CONCLUSION: Effect sizes were not moderated by age, sex, length of treatment, diagnostic subtype initial severity, maximum potential dose, or publication year. It is concluded that pharmacotherapy is effective for treating SAD, but there is considerable variation and room for further improvement. Future directions may include pharmacological enhancement of psychological processes, such as d-cycloserine augmentation of exposure procedures.

Entities:  

Keywords:  meta-analysis; pharmacotherapy; social anxiety disorder

Mesh:

Substances:

Year:  2014        PMID: 25284086     DOI: 10.1517/14656566.2014.955472

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

1.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Neurophysiological predictors of gaze-contingent music reward therapy among adults with social anxiety disorder.

Authors:  Akina Umemoto; Sally L Cole; Grace O Allison; Sarah Dolan; Amit Lazarov; Randy P Auerbach; Franklin Schneier
Journal:  J Psychiatr Res       Date:  2021-09-02       Impact factor: 4.791

Review 3.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

Review 4.  Pharmacotherapy for social anxiety disorder (SAnD).

Authors:  Taryn Williams; Coenraad J Hattingh; Catherine M Kariuki; Sean A Tromp; Anton J van Balkom; Jonathan C Ipser; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2017-10-19

5.  Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.

Authors:  Ymkje Anna de Vries; Annelieke M Roest; Johannes G M Burgerhof; Peter de Jonge
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

Review 6.  Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis.

Authors:  Xue Liu; Xinyuan Li; Congxiao Zhang; Mingze Sun; Ziqian Sun; Yanan Xu; Xiujuan Tian
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

7.  Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials.

Authors:  Xinyuan Li; Yanbo Hou; Yingying Su; Hongping Liu; Beilin Zhang; Shaokuan Fang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.